Breast cancer is the most commonly diagnosed cancer type worldwide and the second cause of cancer-related death in women. Among its subtypes, triple-negative breast cancer (TNBC) represents the most aggressive form, accounting for about 15-20% of all cases. TNBC is characterized by the absence of estrogen (ER), progesterone (PR) and human epidermal growth factor receptor-2 (HER2), making it unresponsive to hormone or HER2-targeted therapies. As a result, TNBC is associated with poor prognosis and a high incidence of early metastasis. Several oncogenic drivers such as KRAS, FOXM1 and eEF2K and the immune checkpoint protein PD-L1 are frequently overexpressed in TNBC, contributing to tumor progression, therapy resistance, and immune evasion, and thus representing potential molecular targets.